阿托伐他汀对冠脉慢血流患者血浆炎性因子的影响  

Effects of atorvastatin on plasma hs-CRP and TNF-α levels in patients with coronary slow flow

作　　者：常快乐[1] 汤洪 于军[1] 李婷[1] 石德红[1] 梁君蓉[1] 

机构地区：[1]解放军第三医院,721004 [2]解放军第451医院

出　　处：《中国医学创新》2012年第3期23-24,共2页Medical Innovation of China

摘　　要：目的 通过对冠状动脉慢血流(CSF)患者临床资料进行分析,观察阿托伐他汀对CSF患者血浆炎性因子的影响。方法 将70例经冠脉造影(CAG)诊断为CSF的患者随机分成治疗组及对照组各35例,患者知情同意,两组均给予单硝酸异山梨酯20mg1次/d,阿司匹林100mg1次/d,曲美他嗪20mg3次/d常规治疗。治疗组加服阿托伐他汀20mg1次/晚。治疗3个月后观察两组患者血浆炎性因子高敏C反应蛋白(hs-CRP)及肿瘤坏死因子(TNF-α)水平的变化。结果 他汀治疗组血浆hs-CRP及TNF-α水平明显减低,两组比较差异有统计学意义(P<0.05)。结论 阿托伐他汀治疗可减轻CSF患者的血浆炎性因子hs-CRP及TNF-α水平。Objective To study the therapeutic effects of atorvastatin in coronary slow flow（CSF） patients through the analysis of their clinical datas and plasma hs - CRP and TNF - α levels. Methods The CSF patients （ n = 70） were divided into control group and treatment group（ given atorvastatin 20 mg daily on the basis of the routine treatment）. The plasma hs- CRP and TNF -α levels of patients were studied after the three months therapy. Results There was a significant difference between the two groups （ P 〈 0.05 ）. The plasma hs - CRP and TNF - α levels significantly decreased in the treatment group compared with control group （ P 〈 0. 05 ）. Conclusion Atorvas- tatin treatments has better therapeutic efficacy in CSF patients with the significant decrease of hs - CRP and TNF - α.

关 键 词：阿托伐他汀 冠状动脉慢血流 高敏C反应蛋白 肿瘤坏死因子 

分 类 号：R543.3[医药卫生—心血管疾病]